Skip to content

Effects of anti osteoporosis therapy on disease outcome and cognitive function in patients with Alzheimer's disease: a prospective randomized controlled study

Effect of anti-osteoporosis treatment on disease outcome and cognitive function of patients with Alzheimer's disease: a prospective randomized controlled study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042909
Enrollment
Unknown
Registered
2021-02-01
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

control group :One-time injection of physiological saline 100ml for patients
experimental group:A one-time intravenous injection of up to 5mg (100ml) for the patient

Sponsors

Gulou Hospital Affiliated to Medical College of Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 60 years old; 2. Through the assessment of cognitive function and cerebrospinal fluid ß- The patients with mild cognitive impairment of Alzheimer's disease were confirmed by amyloid protein detection and head MRI imaging evidence; 3. Patients with osteoporosis: t value measured by bone densitometer was less than 2.5; 4. Patients who agreed to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe renal insufficiency; 2. Patients with severe cardiac insufficiency: NYHA grade IV patients; 3. Patients with active liver disease or severe liver dysfunction; 4. HIV patients; 5. Patients with long-term use of corticosteroids or immunosuppressants and organ transplantation; 6. Pregnant women and lactating women; 7. Patients with malignant tumor; 8. Patients with a history of drug allergy to zoledronic acid and calcitriol; 9. Illiteracy; 10. Patients with a history of neurological diseases such as Parkinson's disease or stroke; 11. Patients who are unable to communicate normally or have severe visual and hearing impairment, etc., and can not cooperate to complete the cognitive function test; 12. Patients with schizophrenia, depression, or other mental diseases; 13. Patients with recent history of taking psychotropic drugs; 14. Patients with basic physical conditions unable to undergo invasive examinations such as lumbar puncture; 15. The patient or his family members refused to participate in the study; 16. Patients combined with other neurotransmitter drugs.

Design outcomes

Primary

MeasureTime frame
BMD;biochemical examination;MMSE;MOCA scale;SF-36;Osteogenic factor;Cerebrospinal fluid examination;Cranial magnetic resonance;

Countries

China

Contacts

Public ContactQing Jiang

Gulou Hospital Affiliated to Medical College of Nanjing University

jiangqing112@hotmail.com+86 13605192953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026